Sable Offshore Corp. Prices Offerings of Common Stock and Convertible Senior Notes

Sable Offshore priced a concurrent equity and convertible notes offering: 32.47M common shares at $3.08/share and $300.0M of 6.5% convertible senior notes due 2031. Net proceeds are estimated at ~$92.8M for common stock (or ~$107.0M if the over-allotment is fully exercised) and ~$288.8M for notes (or ~$332.5M if fully exercised), to be used—along with proceeds from a previously announced New Senior Secured Term Loan—to repay its Senior Secured Term Loan with Exxon Mobil. The notes’ initial conversion price is ~30% premium to the common offering price (≈$4.00/share), implying moderate refinancing/financing dilution risk rather than an operating change.

Analysis

This is a balance-sheet rescue, not a growth financing. The equity+convert structure tells you the market would not fund the story on straight debt, so the incremental capital is really buying time and optionality on a project that still has regulatory and execution risk. For existing holders, the near-term issue is dilution and the implied equity ceiling around the $4 conversion level; for the new capital providers, the yield-plus-option profile is attractive only if the stock can re-rate materially above the deal price.

The second-order winner is not XOM or the broader E&P complex; it is the capital structure itself. If the refinancing closes, distress risk steps down, which can tighten borrow and reduce default-premium volatility, but it also increases the chance of a slow, grinding equity overhang as convert arb desks delta-hedge against any rally. If the company later gets operational/regulatory progress, upside will likely be capped by the new convert supply unless cash flow visibility improves enough to force a repricing of the entire story.

Near term, the biggest catalyst is post-close trading behavior, not the press release. Over 1-3 months, watch whether the stock can hold above the issue price after dilution is absorbed; failure to do so would signal that the market views this as survival capital rather than an accretive reset. Over 6-18 months, the thesis is binary on permitting/production milestones and oil price support; absent those, the capital raise just postpones a larger equity repair.

Contrarian view: the market may be underestimating how much existential risk is being removed by pushing maturities out to 2031, but it is probably not overestimating dilution. The cleanest tell is the stock-convert spread: if SOC trades well below the $4 conversion price after settlement, the notes are effectively expensive debt and the equity remains a financing instrument, not a business-quality re-rating. That argues for caution on chasing any post-close bounce.

Key Decisions for Investors

• Short SOC on any post-close relief rally above the offering price; thesis is dilution/overhang persists while the stock remains below the ~$4 convert strike. Risk is a sharp squeeze on regulatory or restart headlines.
• If already long SOC, reduce exposure into the financing close and only re-enter after the market digests the new share count and convert supply; this is a 1-3 month patience trade, not a same-day pop trade.
• Watch the SOC common vs. convert spread after settlement: if the stock cannot hold above $3.08-$3.25 for several sessions, treat that as confirmation the equity is a capital-structure trade, not a fundamental turnaround.
• No meaningful long XOM expression here; the loan repayment is economically immaterial to Exxon. Use XOM only as a hedge if you want to neutralize crude beta while expressing a bearish SOC-specific view.
• Alert item: if SOC announces material operational or permitting progress before the convert ages into hedge supply, reassess for a tactical long; without that catalyst, the risk/reward skews negatively for common equity.